![Tim Osborne](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 321 957 $ au 30/06/2026
Tim Osborne worked as Principal at the University of California, Irvine.
Mr. Osborne worked as Advisor at Select BioVentures LLC.
Mr. Osborne worked as Senior Vice President-Operations at Forward Air Corp.
from 2013 to 2024.
Mr. Osborne completed undergraduate education at King University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
FORWARD AIR CORPORATION 0,08 % | 15/03/2026 | 23 831 ( 0,08 % ) | 321 957 $ | 30/06/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| FORWARD AIR CORPORATION | Directeur des opérations | - |
Select BioVentures LLC
 Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Private Equity Investor | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
Forward Air Corp.
 Forward Air Corp. TruckingTransportation Provides less-than-truckload, final mile, truckload and intermodal drayage services | Transportation |
King University
 King University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
